ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
Ambrx, Inc.
Ambrx, Inc.
Dana-Farber Cancer Institute
Institut Curie
Icahn School of Medicine at Mount Sinai
Wake Forest University Health Sciences
Dartmouth-Hitchcock Medical Center
M.D. Anderson Cancer Center
The Netherlands Cancer Institute
Tempus AI
Institut Bergonié
UNICANCER
MedSIR
Daiichi Sankyo
MedSIR
MedSIR
Massachusetts General Hospital
University of Wisconsin, Madison
Elevation Oncology
Queen Mary University of London
Actuate Therapeutics Inc.
The Netherlands Cancer Institute
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Dartmouth-Hitchcock Medical Center
Queen Mary University of London
ETOP IBCSG Partners Foundation
ETOP IBCSG Partners Foundation
Fudan University
pharmaand GmbH
Georgetown University
Massachusetts General Hospital
OncoSec Medical Incorporated
iOMEDICO AG
Universitaire Ziekenhuizen KU Leuven
Rutgers, The State University of New Jersey
Duke University
National Institutes of Health Clinical Center (CC)
Fudan University
The Netherlands Cancer Institute
Fudan University
Medstar Health Research Institute
Shanghai Jiao Tong University School of Medicine
G1 Therapeutics, Inc.
The Netherlands Cancer Institute
The Netherlands Cancer Institute
University of Maryland, Baltimore
University of Kansas Medical Center
SCRI Development Innovations, LLC
Centre Leon Berard
MedSIR
Odonate Therapeutics, Inc.